期刊文献+

疾病活动性指标对评估英夫利昔单抗治疗类风湿关节炎早期疗效的作用 被引量:2

Role of disease activity indexes in assessment of early efficacy of rheumatoid arthritis patients with infliximab treatment
下载PDF
导出
摘要 目的探讨疾病活动性指标对评估英夫利昔单抗(IFX)治疗中重度活动性类风湿关节炎(RA)患者早期疗效的作用。方法 14例中重度活动性RA患者初次接受IFX 200 mg滴注,分别于0 h(基线),滴注后3 h、6 h、24 h、3 d、7 d和14 d进行疾病活动性指标评估。主要指标:肿胀关节数目(SJC)、触痛关节数目(TJC)、血清C-反应蛋白(CRP)、血沉(ESR)、疾病活动指数(DAS)28-CRP、健康评估问卷(HAQ)和类风湿因子(RF)。结果 SJC、TJC、CRP、ESR、DAS28-CRP、HAQ及RF等指标均在治疗第14天时明显改善,其中TJC在治疗3 d后开始减少,SJC和HAQ在治疗7 d后改善,CRP和DAS28-CRP于滴注后6 h即开始下降。CRP在3 d时达到低谷,7 d后逐渐回升,14 d时仍低于基线水平。结论 CRP和DAS28-CRP是反映IFX治疗RA早期疗效的最敏感指标,可作为IFX早期疗效的预测因素。 Objective To explore the role of disease activity indexes (DAS) in assessment of early efficacy of rheumatoid arthritis (RA) patients with infliximab (IFX) treatment. Methods 14 patients with moderate and severe activity RA were firstly treated with an intravenous infusion of 200 mg IFX. The levels of the swollen joint count ( SJC ), tender joint count ( TJC ), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), DAS28-CRP, the health assessment questionnaire (HAQ) and rheumatoid factor (RF) were evaluated at 0 hour (baseline), 3,6, 24 hours after infusion and 3, 7 and 14 days after IFX infusion. Results SJC, TJC, CRP, ESR, DAS28-CRP, HAQ and RF improved significantly on 14th day, in which TJC reduced 3 days after treatment, SJC and HAQ improved 7 days after treatment, CRP and DAS28-CRP started to decrease 6 hours immediately after IFX infusion. CRP level was the lowest on third day, and then gradually recovered 7 days after treatment, and remained below the baseline level on 14th day. Conclusion As the most sensitive indexes reflecting the early efficacy of IFX for RA, both CRP and DAS28-CRP can be used as the predictive factors for IFX early efficacy.
出处 《实用临床医药杂志》 CAS 2014年第5期16-19,共4页 Journal of Clinical Medicine in Practice
基金 国家自然科学基金项目(81102274) 成都市科技攻关项目(10GGYB644SF-023) 中国高校医学期刊临床专项资金(11321692)
关键词 类风湿关节炎 英夫利昔单抗 C反应蛋白 疾病活动指数(DAS)28-CRP rheumatoid arthritis infliximab C-reactive protein disease activity index(DAS) 28-CRP
  • 引文网络
  • 相关文献

参考文献22

  • 1Smolen J S, Aletaha D, Bijlsma J W, et al. Treating rheuma- toid arthritis to target: recommendations of an international task force[J]. Ann Rheum Dis, 2010, 69(4) : 631.
  • 2Wiens A, Correr C J, Venson R, et al. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis [ J ]. Clin Rheumatol, 2009, 28 ( 12 ) : 1365.
  • 3Furst D E, Keystone E C, So A K, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012[J]. Ann Rheum Dis, 2013, 72( Suppl 2): ii2.
  • 4Breedveld F C, Han C, Bala M, et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis [J]. Ann Rheum Dis, 2005, 64(1) : 52.
  • 5Smolen J S, Han C, van der Heijde D M, et al. Radiographic changes in rheumatoid arthritis patients attaining different dis- ease activity states with methotrexate monotherapy and inflix- imab plus methotrexate: the impacts of remission and tumour necrosis factor blockade [ J ]. Ann Rheum Dis, 2009, 68 (6) : 823.
  • 6Goekoop-Ruiterman Y P, de Vries-Bouwstra J K, Allaart C F, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : A randomized, controlled trial [ J ]. Arthri- tis Rheum, 2008, 58(2 Suppl) : S126.
  • 7Maini R N, Breedveld F C, Kalden J R, et al. Sustained im- provement over two years in physical function, structural dam- age, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate[ J]. Arthritis Rheum, 2004, 50(4) : 1051.
  • 8Torikai E, Kageyama Y, Takahashi M, et al. The effect of infliximab on bone metabolism markers in patients with rheu- matoid arthritis [ J ]. Rheumatology, 2006, 45 (6) : 761.
  • 9Arvidson N G, Larsen A, Aaseth J, et al. Short-term effects of the TNFa antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis [J]. Scand J Clin Lab Invest, 2007, 67(3) : 337.
  • 10Eklund C M. Proinflammatory cytokines in CRP baseline reg- ulation[ J]. Adv Clin Chem, 2009, 48 : 111.

同被引文献68

  • 1赵慧,汪静,杨喜云,郭建,王宏沛,沈海丽.英夫利昔单抗治疗强直性脊柱炎累及颞颌关节一例[J].中华临床医师杂志(电子版),2011,5(7):2162-2163. 被引量:1
  • 2张卓莉.类风湿关节炎诊断与治疗的递进式发展[J].中国医学前沿杂志(电子版),2013,5(3):30-32. 被引量:7
  • 3Markham A, Lamb H M. Inflximab:a new of its use in the management of rheumatoid arthritis [ J I. Drugs,2000, 59 (6) : 1341 - 1359.
  • 4Smolen J S,Aletaha D, Bijlsma J W,et aL Treating rheumatoid arthritis to target:recommendations of an international task force [ J ]. Ann Rheum Dis,2010,69(4) :631 -637.
  • 5Scheinberg M, Goldenberg J,Feldman D P, et al. Retrospective study e- valuating dose standards for infliximah in patients with rheumatoid arthri- tis at Hospital Israelita Albert Einstein, Sao Paulo, Brazil[ J ]. Clin Rheu- mato1,2008,27 ( 8 ) : 1049 - 1052.
  • 6Elliott M J, Maini R N, Feldmann M, et al. Treatment of rheumatoid ar- thritis with chimeric monoclonal antibodies to tumor necrosis factor alpha [ J 1. Arthritis Rheum, 1993,36 ( 12 ) : 1681 - 1690.
  • 7Pieringer H, Stuby U, Pohanka E, et al. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with inflix- imab[ J]. Clin Rheumato1,2010,29 (7) :723 -727.
  • 8Smolen J S, van Der Heijde D M, St Clair E W, et al. Active - controlled study of patients receiving infliximab for the treatment of rheumatoid ar- thritis of early onset(ASPIRE) study group. Predietors of joint damage in patients with early rheumatoid arthritis treated with high - dose metho- trexate with or without concomitant infliximab : results from the ASPIRE trialC J. Arthritis Rheum,2006, 54(3 ) :702 - 710.
  • 9Allaart C F, Goekoop - Ruiterman Y P, de Vries - Beuwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combi- nation therapy or initial monotherapy strategies:the BeSt study [ J ]. Clin Exp Rheumatol,2006,24(s6) :77 -82.
  • 10Furst D E, Gaylis N, Bray V, et al. Open - label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete re- sponse to etanereept :the opposite study[ J ]. Ann Rheum Dis,2007, 66 (7) :893 -899.

引证文献2

二级引证文献13

;
使用帮助 返回顶部